Controversial drug approval stokes concern about lack of a permanent FDA chief-politico: The Food and Drug Administration’s approval of a controversial new Alzheimer’s drug this week has hardened opposition to acting commissioner Janet Woodcock, who remains President Joe Biden’s apparent favorite to be the agency’s permanent leader.
